We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Electronic Capsule Technology the Basis for Innovations in Personalized Medicine for Women

By LabMedica International staff writers
Posted on 30 Jan 2013
Two European biomedical companies have agreed to collaborate on the development of personalized diagnostic and therapeutic products in the area of women’s health.

Medimetrics BV (Heilbronn, Germany) and the newly formed LiGalli (The Hague, the Netherlands) will be pooling their expertise to develop and produce medical drug delivery and monitoring devices based on Medimetrics' IntelliCap electronic capsule. More...


The IntelliCap electronic capsule is a unique ingestible device that combines five technologies: electronically controlled drug release, laboratory measurement capability, GI tract navigation in the body, two-way real time communication, and the novel operating system. The capsule contains a fluid reservoir and a micro-fluidic pump capable of pumping fluids, pastes, or suspensions. Operation of the pump is controlled by an integrated microprocessor. The IntelliCap also contains sensors that measure the pH and temperature of the pill’s local environment and an ultralow power radio transceiver that allows two-way communication to a data-monitoring/control unit. It is powered by an on-board battery and its electronics are fully sealed to ensure biocompatibility.

LiGalli will contribute its in-depth experience in pharmaceutical and gynecological products to the partnership.

Dr.Willem de Laat, founder of LiGalli said, “This is a significant, but also a logical, step forward in the move towards personalized medicine, improving the diagnostic and therapeutic tools available to patients. Having access to this groundbreaking technology opens the door to developing individualized therapies, which for the first time could meet a woman’s specific needs. It then becomes possible to perform continuous diagnosis monitoring or time exactly when a therapy was delivered, adapt the quantity, and even interrupt the schedule, if necessary.”

Dr. Olaf Weiner, CEO of Medimetrics, said, “The new collaboration adds an exciting dimension within the area of women’s health, creating new and improved therapeutic opportunities for patients. More and more companies are recognizing the potential of our IntelliCap technology, seeking to capitalize on its diagnostic and drug delivery functionalities. It is already widely used by the pharmaceutical industry to rationalize and speed up the development of modified release formulations and dosage forms. By tailoring drug delivery in this way, it is also possible for patients to take their medication less frequently without compromising on efficacy.”

Related Links:
Medimetrics B.V.



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.